Swarajya Logo
  • Morning Brief
  • States
  • Politics
  • Economy
  • Business
  • Culture
  • Infra
  • Defence
  • World
  • Books
  • Ideas
  • Science
  • Technology
  • Heritage
  • Archives
  • Our Views
  • Magazine
  • Headlines
  • Store

mRNA Covid-19 vaccine

India's First mRNA COVID Vaccine Candidate Found To Be Safe, Gets DCGI Nod For Phase 2/3 Clinical Trials

Swarajya Staff
3y News Brief
image

US-Based Moderna Seeks DCGI Approval For Its mRNA COVID-19 Vaccine In India: Report

Swarajya Staff
4y News Brief
image

Pfizer, Moderna Vaccines Can Reduce COVID-19 Infection Risk By 91 Per Cent, Finds US CDC Study

IANS
4y News Brief
image

India’s Biological E Will Make mRNA Covid Vaccine Developed By Canada’s Providence Therapeutics

Bhaswati Guha Majumder
4y News Brief
image

Pfizer Offers Government A "Not-For-Profit" Price For Roll-Out Of Its Two-Dose mRNA COVID-19 Vaccine In India

Swarajya Staff
4y Insta
image

Gennova To Get Additional Govt Funding For India's First mRNA Covid-19 Vaccine Candidate

Swarajya Staff
4y News Brief
image

Get Swarajya in your inbox.


About Swarajya

Shaping the modern Indian's worldview, speaking on behalf of those invested in the cultural and economic prosperity of India. Published since 1956.


Swarajya is a publication by Kovai Media Private Limited.

editor@swarajyamag.com

Useful Links

  • About Us
  • Subscriptions Support
  • Editorial Philosophy
  • Press Kit
  • Privacy Policy
  • Terms of Use
  • Code of Conduct
  • Plagiarism Policy
  • Refund & Cancellation Policy

Useful Links

  • About Us
  • Subscriptions Support
  • Editorial Philosophy
  • Press Kit
  • Privacy Policy
  • Terms of Use
  • Code of Conduct
  • Plagiarism Policy
  • Refund & Cancellation Policy

Participate

  • Contact Us
  • Write for us
  • Style Guide
  • Jobs

Stay Connected

  • Artboard 2 Copy 6Created with Sketch.
    Artboard 2 Copy 10Created with Sketch.
    Artboard 2 Copy 7Created with Sketch.
    Artboard 2 Copy 9Created with Sketch.
  • Andriod Logo
  • IOS Logo